Dr. Finanger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3181 Sw Sam Jackson Park Rd
Cdrc-P
Portland, OR 97239Phone+1 503-494-5856Fax+1 503-494-2370
Education & Training
- Johns Hopkins UniversityFellowship, Neuromuscular Medicine (Neurology), 2008 - 2009
- Johns Hopkins UniversityFellowship, Child Neurology, 2005 - 2008
- Mayo Clinic College of MedicineClass of 2003
Certifications & Licensure
- OR State Medical License 2009 - 2025
- WA State Medical License 2023 - 2025
- MD State Medical License 2008 - 2010
- MN State Medical License 2004 - 2005
- American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology
- American Board of Psychiatry and Neurology Neuromuscular Medicine
Clinical Trials
- A Study of Tadalafil for Duchenne Muscular Dystrophy Start of enrollment: 2013 Sep 01
- A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy Start of enrollment: 2014 Aug 19
- Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy Start of enrollment: 2015 Jun 30
Publications & Presentations
PubMed
- The recurrent deep intronic pseudoexon-inducing variantc.930+189C>T results in a consistently severe phenotype of COL6-related dystrophy: Towards clinical trial readin...A Reghan Foley, Véronique Bolduc, Fady Guirguis, Sandra Donkervoort, Ying Hu
Medrxiv. 2024-03-29 - 2 citationsBiallelic CRELD1 variants cause a multisystem syndrome, including neurodevelopmental phenotypes, cardiac dysrhythmias, and frequent infections.Lauren Jeffries, Emily K Mis, Kirsty McWalter, Sandra Donkervoort, Nina N Brodsky
Genetics in Medicine. 2024-02-01 - 1 citationsClinical importance of changes in magnetic resonance biomarkers for Duchenne muscular dystrophy.Rebecca J Willcocks, Alison M Barnard, Michael J Daniels, Sean C Forbes, William T Triplett
Annals of Clinical and Translational Neurology. 2024-01-01
Press Mentions
- Local Girl Receives First at-Home Treatment for Rare DiseaseNovember 13th, 2020
- Catabasis Pharmaceuticals Reports First Quarter 2020 Financial Results and Reviews Business ProgressMay 12th, 2020
- Edasalonexent May Limit Disease Progression in Boys with Duchenne MD, Phase 1/2 Trial ShowsMarch 1st, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: